🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06798142
Active, not recruiting Observational

Risk Stratification and Heterogeneity for Organ Damage in Acute Diquat Poisoning

NCT06798142 · tracked via the Priya Life Science China tracker
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase
Observational
Started
2022-02-01
Last updated
2026-08-18

Condition(s) studied

Toxic EncephalopathyDiquat Poisoning

Investigational drug(s) / intervention(s)

extracorporeal treatment

extracorporeal treatment: Extracorporeal treatments included hemoperfusion (HP) and continuous veno-venous hemodiafiltration (CVVHDF).

Study summary

This ambispective cohort study aims to characterize the relationship between plasma diquat concentrations and organ damage risk.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion criteria: 1. history of oral exposure to diquat solution reported by patient or proxy; 2. a specimen for the diquat plasma concentration collected immediately upon admission; 3. documentation that patients or, in case of unconsciousness of the patient, legal proxies were aware of and agreed to treatment plans. Exclusion criteria: 1. they had ingested other toxins in addition to diquat (qualitative toxicological screening tests); 2. diquat was not detected in specimens, or plasma concentration data were unavailable; 3. patients with an exposure time (time from exposure to emergency department presentation) longer than 48 hours; 4. data on organ damage were not unavailable; 5. combined with other central nervous system injuries other than toxic encephalopathy.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Nanjing Drum Tower Hospital Nanjing Jiangsu

More The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06798142 on ClinicalTrials.gov ↗ ← All trials in China